In the latest trading session,, 0.73 million Soleno Therapeutics Inc (NASDAQ:SLNO) shares changed hands as the company’s beta touched -2.17. With the company’s most recent per share price at $59.03 changed hands at -$0.01 or -0.01% at last look, the market valuation stands at $2.71B. SLNO’s current price is a discount, trading about -25.36% off its 52-week high of $74.00. The share price had its 52-week low at $36.61, which suggests the last value was 37.98% up since then. When we look at Soleno Therapeutics Inc’s average trading volume, we note the 10-day average is 3.67 million shares, with the 3-month average coming to 1.09 million.
Analysts gave the Soleno Therapeutics Inc (SLNO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SLNO as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Soleno Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Soleno Therapeutics Inc (NASDAQ:SLNO) trade information
Instantly SLNO was in red as seen in intraday trades today. With action -19.87%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 31.33%, with the 5-day performance at -19.87% in the red. However, in the 30-day time frame, Soleno Therapeutics Inc (NASDAQ:SLNO) is 31.83% up. Looking at the short shares, we see there were 4.99 million shares sold at short interest cover period of 8.63 days.
The consensus price target for the stock as assigned by Wall Street analysts is 91.5, meaning bulls need an upside of 35.49% from its recent market value. According to analyst projections, SLNO’s forecast low is 70 with 105 as the target high. To hit the forecast high, the stock’s price needs a -77.88% plunge from its current level, while the stock would need to soar -18.58% for it to hit the projected low.
Soleno Therapeutics Inc (SLNO) estimates and forecasts
8 analysts are of the opinion that Soleno Therapeutics Inc’s revenue for the current quarter will be 2.79M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.19%. The 2025 estimates are for Soleno Therapeutics Inc earnings to increase by 39.57%.
Soleno Therapeutics Inc (NASDAQ:SLNO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.62% of Soleno Therapeutics Inc shares while 109.73% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.68%. There are 109.73% institutions holding the Soleno Therapeutics Inc stock share, with VIVO CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 18.9401% of the shares, roughly 7.32 million SLNO shares worth $298.53 million.
CARLYLE GROUP INC. holds the second largest percentage of outstanding shares, with 10.5395% or 4.07 million shares worth $166.36 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund . With 1.13 shares estimated at $64.81 million under it, the former controlled 2.46% of total outstanding shares. On the other hand, JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund held about 2.04% of the shares, roughly 933.3 shares worth around $53.6 million.
